Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
SPRO
#3193
Spero Therapeutics, Inc. Common Stock
2.1
7
-0.46%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
-0.46%
Monthly Change
-8.05%
6 month change
+10.15%
Cambio anual
+178.21%
Cierres anteriores
2.1
8
Open
2.1
7
Bid
Ask
Low
2.1
7
High
2.1
7
Volumen
8
Markets
Acciones
Atención Sanitaria
SPRO
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Cash from operating activities
12.76 M
-23.4 M
-4 M
-17.69 M
-17.42 M
-62.52 M
Cash from investing activities
—
—
—
—
—
—
Cash from financing activities
220 K
1 000
—
—
—
—
Free cash flow
12.76 M
-23.4 M
-4 M
-17.69 M
-17.42 M
-62.52 M
Noticias
Spero Therapeutics: Tebipenem’s FDA Path Supports A Speculative Buy (NASDAQ:SPRO)
Spero Therapeutics: COO veräußert Aktien im Wert von 44.000 US-Dollar
Keutzer, Spero Therapeutics COO, sells $44k in shares
Insider-Verkauf bei Spero Therapeutics: CEO veräußert Aktien im Wert von 207.000 US-Dollar
Spero Therapeutics CEO sells $207k in stock
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook
Spero Therapeutics announces board resignation and SEC investigation closure
GSK files NDA resubmission for Spero’s tebipenem HBr antibiotic
Spero Therapeutics: EPS übertrifft Schätzungen um 0,26 $ - Umsatz schlechter als erwartet
Spero Therapeutics earnings beat by $0.26, revenue fell short of estimates
Spero Therapeutics: CEO verkauft Aktien nach starkem Kursanstieg
Spero therapeutics CEO Rajavelu sells $95k in stock